Targeted Therapies in Urothelial Carcinoma

Learn about the most clinically influential developments in leveraging immune checkpoint inhibitor–based therapy for first-line, second-line, and maintenance treatment of advanced urothelial carcinoma.

Cora N. Sternberg, MD, FACP Released: February 26, 2021

Review expert guidance on integrating erdafitinib and enfortumab vedotin into management of progressive urothelial carcinoma, then get up to date on key data for sacituzumab govitecan and other promising investigational therapies.

Petros Grivas, MD, PhD Released: February 26, 2021

Download this short summary slideset of key takeaways from a live presentation on integrating targeted agents into the management of progressive urothelial carcinoma.

Petros Grivas, MD, PhD Cora N. Sternberg, MD, FACP Released: March 11, 2021